Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | -0.76% |
|
+2.34% | -62.36% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Samuel Wickline
CTO | Chief Tech/Sci/R&D Officer | 71 | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,240,245 | 2,220,245 ( 99.11 %) | 0 | 99.11 % |
Company contact information
Altamira Therapeutics Ltd.
Clarendon House 2 Church Street
HM 11, Hamilton
+441 295 5950
http://www.altamiratherapeutics.com![address Altamira Therapeutics(CYTO)](https://cdn.zonebourse.com/static/address/125185232.png)
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock
- Company Altamira Therapeutics